Oncology business revenue trends
In 4Q17, Novartis’s (NVS) oncology business generated revenues of $3.24 billion compared to $3.21 billion in 4Q16, which reflected ~1% growth on a YoY basis. In fiscal 2017, Novartis’s oncology business unit reported revenues of $12.5 billion compared to $12.8 billion in 2016, which is a ~4% decline on a YoY basis.
Promacta/Revolade revenue trends
In 4Q17, Novartis’s (NVS) Promacta/Revolade generated revenues of $255 million, which reflected ~43% growth on a year-over-year (or YoY) basis and ~12% growth quarter-over-quarter.
In fiscal 2017, Promacta/Revolade generated revenues of $867 million compared to $635 million in 2016, which reflected ~37% growth on a YoY basis. The increase in the uptake of Promacta worldwide and its increased uptake in use for chronic immune thrombocytopenia led to the drug’s revenue growth.
Votrient revenue trends
In 4Q17, Votrient generated revenues of $213 million, which is ~11% growth on a YoY basis. In 4Q17, Votrient’s quarter-over-quarter revenues remained flat. In fiscal 2017, Votrient reported revenues of $808 million compared to $729 million in 2016, which reflected ~11% growth on a YoY basis.
The sales growth in the US, Europe, and emerging markets was primarily attributed to the revenue growth of Votrient in 2017. Votrient is used to treat advanced renal cell carcinoma (or RCC) and advanced soft tissue sarcoma. Votrient’s competitors include Bristol-Myers Squibb’s Opdivo and Pfizer’s (PFE) Sutent.
Jakavi revenue trends
In 4Q17, Jakavi generated revenues of $228 million, which is ~41% growth on a YoY basis and 13% growth quarter-over-quarter. In fiscal 2017, Jakavi generated revenues of $777 million compared to $581 million in 2016, which reflected ~34% growth on a YoY basis. Jakavi is used for the treatment of myeloproliferative neoplasm.
Kisqali revenue trends
In 4Q17, Kisqali generated revenues of $35 million compared to $26 million in 3Q17, which reflected ~35% quarter-over-quarter growth. In fiscal 2017, Kisqali generated revenues of $76 million. In 4Q17, Kisqali witnessed high growth primarily due to new launches in the different European markets. Kisqali is reimbursed in the UK, Spain, and Germany. Novartis anticipates gaining reimbursement in other European countries over the next 12 months. Kisqali was approved by the U.S. FDA (Food and Drug Administration) in March 2017 for the treatment of HR+/HER2- (human receptor positive, human epidermal growth factor negative) advanced or metastatic breast cancer.